TOLMAR INTERNATIONAL LIMITED

Tolmar International Limited is a global pharmaceutical organisation dedicated to improving the lives of patients and the clinicians who care for them. Specialising in long‑acting injectable therapies, Tolmar focuses on three core therapeutic areas – urology, oncology and endocrinology – with flagship treatments for prostate cancer, central precocious puberty and testosterone‑replacement therapy. Their patient‑first ethos drives every stage of the business, from research and development of more effective formulations to rapid commercialisation and reliable manufacturing that ensures a consistent supply of medicines worldwide.

Supported by a workforce of over 1,100 professionals, Tolmar has produced more than 17 million units since 2002 and now supplies its products in 68 countries. The company’s integrated capabilities span commercialisation, scientific R&D and high‑quality manufacturing, enabling it to address unmet medical needs and expand patient access through strong partnerships. With a clear commitment to sustainability, education and community engagement, Tolmar delivers innovative, long‑acting solutions that enhance real‑life patient experiences across the globe.